Your browser doesn't support javascript.
loading
Plasma Galectin-3 and urine proteomics predict FEV1 improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study.
Riccio, Anna Maria; Mauri, Pierluigi; De Ferrari, Laura; Rossi, Rossana; Di Silvestre, Dario; Bartezaghi, Marta; Saccheri, Fabiana; Canonica, Giorgio Walter.
Afiliação
  • Riccio AM; Allergy & Respiratory Diseases Clinic, DIMI, University of Genoa, Genoa, Italy.
  • Mauri P; Institute Biomedical Technologies, ITB-CNR, Segrate, Italy.
  • De Ferrari L; Allergy & Respiratory Diseases Clinic, DIMI, University of Genoa, Genoa, Italy.
  • Rossi R; Institute Biomedical Technologies, ITB-CNR, Segrate, Italy.
  • Di Silvestre D; Institute Biomedical Technologies, ITB-CNR, Segrate, Italy.
  • Bartezaghi M; Novartis Farma SpA, Origgio, Italy.
  • Saccheri F; Novartis Farma SpA, Origgio, Italy.
  • Canonica GW; Department of Biomedical Sciences, Personalized Medicine Clinic Asthma & Allergy,Humanitas University, IRCCS Humanitas Research Hospital, Rozzano, Italy.
World Allergy Organ J ; 13(1): 100095, 2020 Jan.
Article em En | MEDLINE | ID: mdl-32015785
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: World Allergy Organ J Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: World Allergy Organ J Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália